ALAN G. MALLINGER, M.D.
Professor of Psychiatry and Pharmacology
University of Pittsburgh School of Medicine
Director, Psychopharmacology of Mania and Depression Program
Western Psychiatric Institute and Clinic
Pittsburgh, Pennsylvania

During his career, Dr. Mallinger has pursued parallel interests in clinical psychiatry and basic psychopharmacology research related to mood disorders. His areas of basic research interest include laboratory studies on cell membrane phenomena and intracellular signal transduction processes, specifically, as these relate to the biological aspects of bipolar disorder and to the therapeutic mechanisms of mood stabilizing drugs. His clinical research interests include therapeutic options for treatment-resistant mania, mood stabilizer treatment during pregnancy, and pharmacokinetic studies of MAO inhibitors. He has been involved in various clinical trials on antidepressants, mood stabilizers, and psychotherapy. Dr. Mallinger has authored or co-authored 56 scientific articles and book chapters. He is currently Director of the Psychopharmacology of Mania and Depression basic research program at WPIC, as well as Medical Director of the Maintenance Therapies in Bipolar Disorder study, and the Stanley Center for the Innovative Treatment of Bipolar Disorder. He also served as Chairperson of the Merit Review Committee for Mental Health and Behavioral Sciences for the Department of Veterans Affairs, Washington, D.C.. He is Course Director of the Pharmacotherapy Training in Mood Disorders Clinic and the Mood Disorders Seminar for psychiatry residents at the University of Pittsburgh.

HUSSEINI K. MANJI, M.D., F.R.C.P.C.
Professor of Psychiatry and Behavioral Neurosciences and Pharmacology
Director, Laboratory of Molecular Pathophysiology
Wayne State University School of Medicine

Husseini K. Manji, M.D. is Founding Director of the Laboratory of Molecular Pathophysiology and the Founding Director of the Neuropsychiatric Research Unit, Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine. Dr. Manji received his B.S. (Biochemistry) and M.D. from the University of British Columbia. He subsequently completed fellowship training in psychopharmacology at the NIMH and additional research training in Cellular and Molecular Biology at the NIDDK. He is actively involved in research investigating the molecular and cellular mechanisms of action of mood-stabilizing agents. He established and is the original Director of a new Neuropsychiatric Research Unit which conducts an integrated series of clinical and preclinical studies which focus on signal transduction pathways in mood disorders. He has received research funding from the NIH for his work on signaling pathways, and has attracted considerable funding from foundations and the pharmaceutical industry in the area of medication development. Dr. Manji is a previous recipient of the A.E. Bennett Award for Neuropsychiatric Research, the NIMH award for excellence in clinical care and research, NARSAD Independent Investigator Award, and the Canadian Association of Professors in Psychiatry Award. He has published extensively on the molecular and cellular mechanisms of action of mood-stabilizing agents and antidepressants, and is the co-editor on a forthcoming book on the mechanisms action of antibipolar treatments. He is a Councillor of the Canadian College of Neuropsychopharmacology, a member of the Ethics Committee of the American College of Neuropsychopharmacology, and sits on the Editorial Board of the official journals of both the ACNP and CINP. He has served the NIH over the years as an ad hoc reviewer on Review Committees, and advisory boards, and is a member of the National Board of Medical Examiners Behavioral Science Test Committee, and a member of the USMLE Step 1 Test Material Development Committee for Behavioral Science.

KATHLEEN RIES MERIKANGAS, Ph.D.
Professor of Epidemiology and Public Health, Psychiatry, and Psychology
Director, Genetic Epidemiology Research Unit
Yale University School of Medicine
New Haven, Connecticut

Dr. Kathleen Merikangas is Professor of Epidemiology and Public Health, Psychiatry, and Psychology, and Director of the Genetic Epidemiology Research Unit at the Yale University School of Medicine. She is also an Adjunct Associate Professor at the University of Pittsburgh School of Medicine. Dr. Merikangas has formal training in clinical psychology, chronic disease epidemiology, and human genetics. She has received Research Scientist Development Awards from the National Institute of Mental Health and the National Institute of Drug Abuse of the U.S. Public Health Service. She is the recipient of numerous federal and non-federally funded research grants and is the Co-Director of a training program in Psychiatric Epidemiology at the Department of Public Health at Yale.

Dr. Merikangas has more than 150 scientific publications and she is on the Editorial Board and reviews for numerous several scientific journals. She has presented lectures throughout the U.S. as well as in more than 15 countries. She is a member of the Core Scientific Advisory Panel for the MacArthur Foundation Network on Psychopathology and Development and the Robert Wood Johnson Foundation Interdisciplinary Research Network on the Etiology of Tobacco Dependence. She has also served on Review Committees of the National Institute of Mental Health, the National Institute of Drug Abuse, the National Institute of Alcohol Abuse and Alcoholism, the National Advisory Mental Health Council Work Group on Mental Disorders Prevention Research, and is on the advisory panels of several other scientific organizations both in the U.S. and abroad.

Dr. Merikangas is currently the Director of the Genetic Epidemiology Research Unit, which has the major goal of employing the methods of genetic epidemiology to identify individual and environmental risk factors for psychiatric and neurologic disorders. Current research projects include: "International Community Studies of Psychiatric Disorders and Medical Disorders"; "Family Studies of Comorbidity of Substance Abuse and Psychiatric Disorders"; "Longitudinal Studies of Vulnerability for Psychiatric and Substance Disorders"; "Psychophysiologic Vulnerability Markers for Anxiety"; "Migrant Study of Puerto Rican Families"; "Family Study of African Americans in New Haven Community"; "Influence of Puberty on Emotional Functioning"; and "Prevention Programs for Adolescents: Primary Prevention of Secondary Disorders". The basic features of the research at this unit include: a multidisciplinary research team; a broad span of public health approaches including descriptive epidemiology, analytic epidemiology and prevention; integration of genetic, biologic and psychosocial risk factors; and studies of a wide range of public health problems including; anxiety, depression, drug abuse, alcoholism, smoking, migraine, and asthma.

DAVID J. MIKLOWITZ, Ph.D.
Professor of Psychology
Department of Psychology (Clinical Area)
University of Colorado at Boulder

Dr. Miklowitz did his undergraduate work at Brandeis University and his doctoral (1979-1985) and postdoctoral work (1985-88) at UCLA. He has been at University of Colorado, Boulder since 1989. His specialty is in the family environmental factors associated with bipolar disorder. He has received Young Investigator Awards from the International Congress on Schizophrenia Research and the National Alliance for Research on Schizophrenia and Depression. He has received funding for his research from the National Institute for Mental Health and the MacArthur Foundation. He has published 70 research papers on bipolar disorder and schizophrenia. His articles have appeared in the Archives of General Psychiatry, the British Journal of Psychiatry, the Journal of Nervous and Mental Disease, and the Journal of Abnormal Psychology. His book with Michael Goldstein, published by Guilford Press, "Bipolar Disorder: A Family-Focused Treatment Approach," recently won the Outstanding Research Publication Award from the American Association of Marital and Family Therapy.

GREGORY J. MOORE, Ph.D.
Assistant Professor of Psychiatry and Behavioral Neurosciences and Radiology
Scientific Director, Brain Imaging Research Program
Wayne State University School of Medicine
Detroit, Michigan

Dr. Gregory J. Moore is a Neuroscientist and Magnetic Resonance Physicist who received his Ph.D. from MIT in 1992. He is currently Scientific Director of the Brain Imaging Research Program at Wayne State University School of Medicine and is Assistant Professor in the Departments of Psychiatry and Behavioral Neurosciences and Radiology. His research interests are diverse and highly interdisciplinary ranging from basic science studies for developing MR imaging techniques with molecular scale resolution for novel pharmaceutical development, pre-clinical studies in rodents, to clinical studies in pediatric and adult neuropsychiatric and neurological disorders utilizing magnetic resonance spectroscopy to non-invasively monitor cerebral neurochemistry. A particular area of research focus involves the study of neurochemistry and treatment response in manic-depressive illness. Dr. Moore currently has nearly $1 million in extramural support for his research programs from national foundations (NARSAD and NAMI-Stanley Foundation) and the National Institutes of Health. Dr. Moore serves as a reviewer for 6 professional journals, has won several prestigious awards, been an invited expert panelist to the NIMH, serves as a VA Merit grant reviewer, is a frequent invited speaker at international scientific meetings, and has authored numerous scientific papers, book chapters and patents.

PAOLO LUCIO MORSELLI, M.D.
Vice-President, Fondazione IDEA-Milano, Italy
Secretary General, GAMIAN-Europe

Professor Morselli joined the Pharmacology Department at the Medical College of Virginia, USA as a Fulbright-Hayes scholar after completing a degree in Medicine and a specialization in Psychiatry from the University of Milan, Italy in 1964. In 1967 Professor Morselli returned to Italy where he was appointed as Head of the Clinical Pharmacology Unit at the "Mario Negri Institute" in Milano. In 1976 he took charge as the Director of the Clinical Research Department of the Laboratoires d’Etudes e de Recherches Synthelabo. In 1990 he was appointed Vice-President of Synthelabo Recherche Division. In 1992 he was appointed Corporate Vice-President in charge of Medical Affairs of Synthelabo Co. He served in this position till 1994. Professor Morselli has also served as Associated Scientist at the "Istitute Philippe Pinel de Montreal" Canada from 1993-1994. Since 1991, he has been a "Visiting Professor" in Clinical Neuro-psychopharmacology at the departments of Clinical Psychopharmacology and Psychiatry at "Hopital Trias y Pujol"-Badalona, Universidad Autonoma de Barcelona, Spain.

Since 1995, Professor Morselli’s main areas of interest have been patient and GPs education, the social and therapeutic aspects of depression, the problems linked to stigma and prejudices associated with depression and other mental illnesses. He is one of the charter members of GAMIAN (Global Alliance of Mental Illness Advocacy Networks). Since 1995, he has served as Scientific Advisor to the Italian patient group, "Fondazione IDEA", where he is currently Vice-President. He was also the Secretary General of GAMIAN from 1997 to 1998, before GAMIAN divided its internal organizational structure. He has continued to serve as Secretary General of GAMIAN-Europe.

Professor Morselli is a member of several scientific organizations and on the Editorial Board of 13 international scientific journals. He has authored or co-authored 476 scientific publications and served as editor or co-editor of 17 scientific specialized monographs in the field of neuropsychiatry and clinical pharmacology.

Professor Morselli’s contributions to his field were recognized by the "Ambrogino d’oro" from the Comune di Milano in 1973, the ASPET/ILAE research award for "outstanding contribution in the development of anti-epileptic drugs" in 1978 and the ILAE award for "the best published clinical trial on AED" in 1979.

ERIC J. NESTLER, M.D., Ph.D.
Elizabeth Mears and House Jameson Professor
Psychiatry, Pharmacology, and Neurobiology
Yale University School of Medicine
New Haven, Connecticut

Dr. Nestler received his B.A. in 1976, Ph.D. in 1982, and M.D. in 1983, all from Yale University. After completing residency training in psychiatry at McLean Hospital and Yale in 1987, he joined the Yale faculty where he is now the Elizabeth Mears and House Jameson Professor of Psychiatry, Pharmacology, and Neurobiology. Since 1992, Dr. Nestler has served as Director of the Abraham Ribicoff Research Facilities and of the Division of Molecular Psychiatry.

Dr. Nestler is the recipient of numerous awards and honors, including the Pfizer Scholars Award (1987), Sloan Research Fellowship (1987), McKnight Scholar Award (1989), Efron Award of the American College of Neuropsychopharmacology (1994), and Pasarow Foundation Award for Neuropsychiatric Research (1998). He serves on the Board of Scientific Advisory Boards of the National Alliance for Research in Schizophrenia and Depression and of the National Alliance for Autism Research. Dr. Nestler was elected to the Institute of Medicine in 1998.

The goal of Dr. Nestler’s research is to better understand the ways in which the brain responds to repeated perturbations under normal and pathological conditions. A major focus of the research is drug addiction: to identify molecular changes that drugs of abuse produce in the brain to cause addiction, and to characterize the genetic and environmental factors that determine individual differences in the ability of the drugs to produce these changes. This work is based on the view that a greater knowledge of the neurobiological basis of drug addiction will lead to more effective treatments and preventive measures. Similar work is underway in the areas of depression, psychosis, and stress.

ATUL C. PANDE, M.D., F.R.C.P.C.
Senior Director, Psychiatry
Parke-Davis Pharmaceutical Research
Ann Arbor, Michigan

Atul Pande, M.D., F.R.C.P.C. received his medical education at the King George’s Medical College at the University of Lucknow in Lucknow, India. He obtained specialty training in Psychiatry at the same institution followed by additional training in Jamaica, Canada and the USA.

He went on to become Assistant Professor of Psychiatry at the University of Michigan Medical School in Ann Arbor, Michigan. In this position, he was involved in teaching, research and the clinical practice of psychiatry. His main area of research specialization was depressive illness, with particular emphasis on biological treatments. In 1992, he moved to take a position as Clinical Research Physician at Lilly Research Laboratories in Indianapolis where he worked on further clinical development of fluoxetine. In 1994, he was appointed Director of CNS Clinical Research at Parke-Davis Pharmaceutical Research in Ann Arbor, and in 1996 was promoted to Senior Director with responsibility for the worldwide development of psychotropic drugs. He currently oversees new drug development efforts in depressive, anxiety and psychotic disorders.

STEVEN MARC PAUL, M.D.
Vice President, Lilly Research Laboratories
Eli Lilly and Company
Professor of Pharmacology, Toxicology and Psychiatry
Indiana University School of Medicine
Indianapolis, Indiana

Steven Marc Paul, M.D. joined Eli Lilly and Company in April of 1993, as a Vice President of the Lilly Research Laboratories responsible for Central Nervous System (CNS) Discovery and Decision Phase Medical Research. In 1996, Dr. Paul was appointed Vice President (and in 1998 Group Vice President) of Therapeutic Area Discovery Research and Clinical Investigation. Dr. Paul is responsible for the preclinical therapeutic area discovery research, toxicology, chemistry, project management, and decision phase medical research of the Lilly Research Laboratories. Prior to assuming his position at Lilly, Dr. Paul served as Scientific Director of the Intramural Research Program (IRP) of the National Institute of Mental Health (NIMH/NIH) in Bethesda, Maryland.

Dr. Paul received his Bachelor of Arts degree, Magna Cum Laude with honors in Biology and Psychology from Tulane University, in 1972. He received his Master of Science degree in Anatomy (Neuroanatomy) and his Doctor of Medicine degree, both in 1975, from the Tulane University School of Medicine. Following an internship in Neurology at Charity Hospital in New Orleans, he served as a resident in Psychiatry and an Instructor in the Department of Psychiatry at the University of Chicago, Pritzker School of Medicine.

In 1976, he was awarded a research fellowship in the Pharmacology Research Associate Training Program of the National Institute of General Medical Science (NIGMS), to work with Nobel Laureate Dr. Julius Axelrod in the Laboratory of Clinical Science, IRP, of the NIMH. In June 1978, he became a Clinical Associate in the Clinical Psychobiology Branch of NIMH, and served in that position for two years. In 1982, Dr. Paul was appointed Chief of the Clinical Neuroscience Branch as well as Chief of the Section on Preclinical Studies, IRP, NIMH. In addition to serving as the Scientific Director of NIMH (1988-1993), Dr. Paul has held appointments as an Adjunct Professor of Pharmacology in the Uniformed Services University of the Health Sciences; Adjunct Professor of Psychiatry at the University of Maryland School of Medicine; Adjunct Professor of Psychiatry at the Medical College of South Carolina; Clinical Professor of Psychiatry at the Tulane University School of Medicine; Adjunct Professor of Pharmacology at Boston University School of Medicine and recently Professor of Pharmacology, Toxicology and Psychiatry at the Indiana University School of Medicine.

Prior to assuming his position at the Lilly Research Laboratories, Dr. Paul also served as Medical Director in the Commissioned Corps of the United States Public Health Service, and maintained a private practice in Psychiatry and Psychopharmacology. He is Board Certified by the American Board of Psychiatry and Neurology and has been elected a Fellow in the American College of Neuropsychopharmacology (ACNP), the American College of Psychiatrists, and the Collegium Internationale NeuroPsychopharmacologicum (CINP). He is currently President-Elect of the ACNP.

Dr. Paul is currently licensed to practice medicine in the state of Maryland.

Dr. Paul is a member of various professional and honorary societies, which include the Tulane Scholars and Fellows; Phi Eta Sigma; Alpha Epsilon Delta: Sigma Xi; Phi Beta Kappa; and the Alpha Omega Alpha Honorary Medical Society. He is the recipient of many honors and scientific recognitions, including: The A.E. Bennett Award of the Society of Biological Psychiatry; the Arthur S. Flemming Award by the Downtown Jaycees (outstanding research by a government employee); the Allan C. Davis medal (Outstanding Young Scientist Award) of the Maryland Academy of Sciences; the Foundations’ Fund Prize for Research of the American Psychiatric Association, the Daniel H. Efron Award of the American College of Neuropsychopharmacology (ACNP); the Max Hamilton Award of the Collegium Internationale NeuroPsychopharmacolgicum (CINP); and the Distinguished Service Medal of the USPHS. In 1997, Dr. Paul was elected to membership in the Institute of Medicine of the National Academy of Sciences.

Dr. Paul’s own research activities have established an important role for specific neurotransmitter receptors in mediating the central actions of various neuroactive drugs. Among his many contributions has been the delineation of the role of receptors for the inhibitory neurotransmitter GABA in mediating the behavioral effects of benzodiazepines, barbiturates, short-chain alcohols as well as a novel class of neuroactive steroids. He is currently working on new therapeutic approaches for Alzheimer’s disease and other neurodegenerative disorders.

Dr. Paul has authored or co-authored over 450 papers and invited book chapters, serves on the Editorial Boards of several scientific journals, and as a grant reviewer for several extramural and intramural committees, and is a member of the National Advisory Medical Sciences Council, NIH. He has recently been listed as one of the most highly cited pharmacologists in the world (1982-1992) by the I.S.I., Philadelphia, Pennsylvania.

William Z. Potter, M.D., Ph.D. has been Executive Director and Lilly Clinical Research Fellow of the Neuroscience Therapeutic Area at Lilly Research Laboratories since January, 1996. He developed a Lilly/IU fellowship early in 1996 and was named Professor of Psychiatry at IUMC. Before being associated with Lilly Research Laboratories, he held the position of Chief, Section on Clinical Pharmacology, Intramural Research Program at the National Institute of Mental Health in Bethesda, Maryland. He had been with the Public Health Service and the National Institutes of Health since 1971.

Born in Charleston, South Carolina, he attended Western Reserve Academy in Hudson, Ohio, Eastbourne College, in Eastbourne, Sussex, England, he received his B.A. (Philosophy) from Indiana University in 1968 and received his M.D. and Ph.D. at Indiana University in 1970 and 1972, respectively. He was Board Certified in Psychiatry in 1978 and in Clinical Pharmacology in 1979.

Dr. Potter belongs to many societies in which he has served in numerous capacities as an officer, board member or scientific program committee member including the American Society for Clinical Pharmacology and Therapeutics, American College of Neuropsychopharmacology, Society of Biological Psychiatry, American Psychiatric Association, American Society of Clinical Psychopharmacology, Inc. and Collegium Internationale Neuro-Psychopharmacologium.

He also serves on various editorial boards including that of the Archives of General Psychiatry, Clinical Pharmacology and Therapeutics, Depression, Journal of Psychopharmacology, Psychopharmacology Bulletin, and U.S. Consulting Editor to Therapeutic Drugs as well as serving as a reviewer for the major pharmacological and clinical research journals.

He has authored more than 200 publications in the field of pre-clinical and clinical pharmacology, mostly focused on drugs used in affective illnesses. He is considered to be a "World Opinion Leader" in manic-depressive illness. He has received many honors during his career. Some of those include the 1975-1977 Falk Fellow, American Psychiatric Association, 1986 Meritorious Service Medal, United States Public Health Service and in 1990, St. Elizabeth’s Residency Program Alumnus of the Year Award.

Dr. Renshaw is Director of the Brain Imaging Center at McLean Hospital and Associate Professor of Psychiatry at Harvard Medical School. His research interests are focused on the use of multinuclear magnetic resonance spectroscopy (MRS) and functional magnetic resonance imaging (fMRI) to assess individuals with psychiatric and substance abuse disorders. Over a decade ago, Dr. Renshaw demonstrated that lithium MRS could be used to measure brain lithium levels in persons who take lithium therapeutically. He continues to use MRS methods to characterize changes in brain chemistry associated with bipolar disorder and psychopharmacologic agents. Dr. Renshaw’s research has been supported by the National Alliance for Research in Schizophrenia and Depression (NARSAD), the Stanley Foundation, the National Institute on Mental Illness, and the National Institute on Drug Abuse. He has served as a grant reviewer for the Center for Scientific Review at the National Institutes of Health and he is currently a member of the Veterans Administration Behavioral Science Merit Review Board. In addition, Dr. Renshaw recently accepted an appointment on the National Advisory Council on Drug Abuse.

NOREEN REILLY-HARRINGTON, Ph.D.
Instructor in Psychology
Harvard Medical School
Clinical Fellow in Psychology
Massachusetts General Hospital
Boston, Massachusetts

Dr. Reilly-Harrington is an Instructor in Psychology at Harvard Medical School and a Clinical Psychologist in the Harvard Bipolar Research Program at Massachusetts General Hospital. She earned her doctoral degree at Temple University and trained in cognitive therapy under the mentorship of Dr. Aaron T. Beck at the Center for Cognitive Therapy, University of Pennsylvania and at the Beck Institute for Cognitive Therapy and Research. She specializes in the cognitive-behavioral treatment of bipolar disorder and has lectured both nationally and internationally on this topic. Dr. Reilly-Harrington is the leader of cognitive-behavioral treatment in the NIMH Systematic Treatment Enhancement Program for Bipolar Disorder. She has received recognition from the Society for Research in Psychopathology, Association for the Advancement of Behavior Therapy, and Massachusetts General Hospital for her work examining the role of life stress and cognition on the course of bipolar mood disorders. Dr. Reilly-Harrington is also involved in studies examining neuropsychological functioning in bipolar disorder, communication patterns in spouses of patients with bipolar disorder, and the use of cognitive-behavioral weight management strategies for medication-related weight gain in bipolar disorder.

For over 25 years, Dr. Rush has conducted clinical investigations that span both biological and psychosocial issues in mood disorders in adults, children, and adolescents, and promoted the application of clinical research findings to improve the diagnosis and treatment for these patients. Publications include over 225 papers and chapters and 8 books.

He is a graduate of Princeton (BA Biochemistry, 1964); Columbia University College of Physicians and Surgeons (MD, 1968); Northwestern University (Internship in Internal Medicine, 1969); and the University of Pennsylvania (Psychiatric Residency, 1972-75). He served in the US Army (1969-71), and in the Special Action Office for Drug Abuse Prevention, Washington, DC (1971-72).

Dr. Rush is a Fellow of the American Psychiatric Association, the American College of Neuropsychopharmacology, and the American College of Psychiatry. He has served as President of the Society for Psychotherapy Research, and the Society of Biological Psychiatry. He chaired the DSM-IV Workgroup on Mood Disorders, and the Panel on Practice Guidelines for Depression in Primary Care for the Agency for Health Care Policy and Research. He has also served on NIMH and VA Merit Review Committees, and is an editorial board member, reviewer, or consultant for over a dozen psychiatric journals.

His most recent honors include being named Exemplary Psychiatrist by the Dallas Alliance for the Mentally Ill (1996 and 1997), Outstanding Psychiatrist of the Year by the Texas Society of Psychiatric Physicians (1995), corecipient of the Gerald L. Klerman Lifetime Research Award of the National Depressive and Manic Depressive Association (1994), and the Professional of the Year Award from the Dallas Alliance for the Mentally Ill (1994). He has received the Strecker Award (Institute of Pennsylvania Hospital) and the Charles C. Burlingame Award (Institute of Living) in recognition of his research, teaching, and clinical work.

Gary Sachs, M.D. is the director of the Bipolar Research Program at Massachusetts General Hospital and Assistant Professor of Psychiatry at Harvard Medical School. He is the principal investigator of the NIMH sponsored Systematic Treatment Enhancement Program for Bipolar Disorder.

Dr. Sachs graduated from the University of Pennsylvania and attended graduate school at Cambridge University. He earned his medical degree from the University of Maryland School of Medicine and served his internship in Family Practice and Psychiatry at the University of Maryland Hospital in Baltimore. After completing a residency in Psychiatry and a chief residency in the Acute Psychiatry Service, at Massachusetts General Hospital, Dr. Sachs completed an MGH Fellowship in the Inpatient Psychopharmacology Unit with Dr. Alan Gelenberg.

Dr. Sachs is an active author, lecturer, and research scientist. His major research interests include bipolar mood disorders, psychopharmacology, chronobiology, and the use of treatment guidelines in clinical practice. Dr. Sachs has authored more than 70 articles, abstracts and book chapters.

Dr. Simpson is Associate Professor of Psychiatry at the Johns Hopkins University School of Medicine and Director of the Affective Disorders Consultation Clinic at the Johns Hopkins Hospital. Since 1986 she has been a co-investigator in genetic studies of bipolar I disorder (manic-depressive illness), directing the recruitment and clinical evaluation of bipolar families. She helped write the Diagnostic Interview for Genetics Studies (DIGS) and helped train interviewers for the NIMH Genetics Initiative for Bipolar Disorders. She was the recipient of two Young Investigator Awards from the National Alliance for Research in Schizophrenia and Depression (NARSAD). Her clinical interests include depression in women, bipolar II disorder and other difficult-to-treat forms of bipolar disorders. She has published articles on depression, bipolar disorder (particularly bipolar II disorder), and suicide. She is a reviewer for several journals including the American Journal of Psychiatry, Neuropsychiatric Genetics, Journal of Psychiatric Research, and Depression. She attends on the Affective Disorders Inpatient Unit four months per year, and is involved in teaching residents and medical students.

JAIR C. SOARES, M.D.
Assistant Professor of Psychiatry
University of Pittsburgh School of Medicine
Director, Neurochemical Brain Imaging Laboratory
Western Psychiatric Institute and Clinic
Pittsburgh, Pennsylvania

Dr. Jair C. Soares graduated in 1990 from the University of Sao Paulo School of Medicine, Brazil. After psychiatric residencies at the University of Sao Paulo (1991-1993), and at the Western Psychiatric Institute and Clinic, University of Pittsburgh (1993-1997), he took a brain imaging fellowship at the department of Psychiatry at Yale University (1997-1999). He has held an appointment as an Assistant Professor of Clinical Psychiatry at the University of Pittsburgh School of Medicine since 1997, and recently joined its faculty on a full-time basis as an Assistant Professor of Psychiatry. Dr. Soares had had extensive clinical research experience in the field of bipolar and mood disorders, and expertise with neuroimaging modalities as research tools to investigate these disorders. Since 1998, he has been co-editing with Dr. Samuel Gershon, at the University of Pittsburgh, a new peer-review journal called "Bipolar Disorders – An International Journal of Psychiatry and Neurosciences". He recently started to direct the Neurochemical Brain Imaging Laboratory at Western Psychiatric Institute and Clinic, University of Pittsburgh, which is a new clinical research program dedicated to conducting studies that use new brain imaging modalities to attempt to elucidate causation of bipolar and unipolar mood disorders, and the mechanisms of action of treatments for these conditions.

Dr. Trisha Suppes is an Associate Professor of Psychiatry at UT Southwestern Medical Center, Director of the Bipolar Disorder Clinic and Research Program, and Principal Investigator for Stanley Foundation Bipolar Network Dallas site. Her early work in basic neurosciences focused on modulation of excitability using single cell recordings in vitro and mammalian hippocampal brain slices. During her residency at McLean Hospital and Fellowship in Neurocience at Harvard Medical School, she studied the discontinuation of lithium for patients with bipolar disorder. The result of this metaanalysis supported the importance of bipolar disorder patients continuing on medication. Her work on treatment and management of refractory patients with a history of mania led to a randomized, open trial of clozapine add-on v.s. treatment-as-usual showing both acute and prophylactic mood stabilizing properties for this atypical antipsychotic, even in patients with no history of psychosis. She is currently focused on the use of treatment guidelines for bipolar patients in the Texas Medication Algorithm Project, where she is Director of the bipolar module.

HOLLY SWARTZ, M.D.
Assistant Professor of Psychiatry
University of Pittsburgh School of Medicine
Western Psychiatric Institute and Clinic
Pittsburgh, Pennsylvania

Holly Swartz, M.D. received her bachelor’s degree from Harvard University and her medical degree from Albert Einstein School of Medicine. She completed her residency training in psychiatry at Payne Whitney Clinic and Reader’s Digest Research Fellowship at Cornell University Medical Center in New York City. Her research interests include interpersonal psychotherapy for treatment resistant populations, psychosocial treatments for bipolar disorders and barriers to care for women with mood disorders. She joined the faculty of the University of Pittsburgh School of Medicine in 1997 as a researcher and staff psychiatrist for the Depression and Manic Depression Prevention Program

MICHAEL E. THASE, M.D.
Professor of Psychiatry
University of Pittsburgh School of Medicine
Chief, Division of Academic Adult Psychiatry
Western Psychiatric Institute and Clinic
Pittsburgh, Pennsylvania

Michael E. Thase, M.D. is a Professor of Psychiatry at the University of Pittsburgh School of Medicine and the Western Psychiatric Institute and Clinic. He is an active clinical investigator, whose research focuses on the assessment and treatment of mood disorders, including the short-term and prophylactic efficacy of pharmacotherapy and cognitive therapy in relationship to the psychobiological correlates of depression. A 1979 graduate of the Ohio State University College of Medicine, Dr. Thase has directed the Depression Treatment and Research Program at the University of Pittsburgh since its inception in 1987. In 1988, he was appointed Associate Director of their Mental Health Clinical Research Center and is now the Chief of Adult Psychiatry. Dr. Thase has authored or co-authored over 250 scientific articles and book chapters. He is co-editor of the books entitled Handbook of Outpatient Treatment, published in 1990 by Plenum Press, and Cognitive Therapy with Inpatients: Developing a Cognitive Milieu, which was published in 1992 by the Guilford Press.

Mauricio Tohen, M.D., Dr.P.H., graduated as a doctor of medicine from the National University of Mexico in 1976 and as a doctor of public health (epidemiology) from Harvard University in 1988. His postdoctoral training included a residency in psychiatry at the University of Toronto (1979-1985). From 1988 to 1997, he was clinical director of the Bipolar and Psychotic Disorder Program at McLean Hospital. In 1997, he joined Eli Lilly and Company as a Medical Advisor. He is also an Associate Clinical Professor of Psychiatry at Harvard Medical School.

He received a National Service Award in Psychiatric Epidemiology from NIMH and Harvard University. He also received a FIRST award from NIMH, the Pope Award from McLean Hospital, and a NARSAD Young Investigator Award. Dr. Tohen’s research, supported by grants from NIMH and the pharmaceutical industry, has focused on the epidemiology, outcome, and treatment of bipolar disorder.

He has served on the Council on Research and the committee on Health Services Research of the American Psychiatric Association. He has also served in the Epidemiology & Genetics and the Clinical Centers and Special Projects Review committees at NIMH. Dr. Tohen has over 100 publications. He co-edited two books, Psychiatric Epidemiology (1995) and Mood Disorders Across the Life Span (1996). He also edited the book Comorbidity in Affective Disorders (1999).

MICHAEL VON KORFF, Sc.D.
Associate Director, External Research
Center for Health Studies
Group Health Cooperative of Puget Sound
Seattle, Washington

Dr. Von Korff is Associate Director for External Research of the Center for Health Studies, Group Health Cooperative of Puget Sound. He is also an affiliate Professor in the Departments of Psychiatry and Health Services of the University of Washington Schools Medicine and Public Health. His major research interests are the management and outcomes of depression and of chronic pain among primary care patients, and determinants of disability and health care use in these patient populations. He has been co-principal investigator of a series of NIMH-funded randomized trials of new approaches to managing depressed patients in primary care settings. He recently led work on two large randomized controlled trials of interventions to improve self-management of chronic-recurrent back pain. He is co-Principal Investigator of the Robert Wood Johnson Foundation's National Program for Improving Chronic Illness Care in organized health care systems. Dr. Von Korff has participated in the design and conduct of several major mental disorder morbidity surveys, including the NIMH Epidemiologic Catchment Area surveys and the World Health Organization's Collaborative Study of Psychological Problems in General Health Care Settings. He serves as an advisor to the World Health Organization's initiative on assessing disability. Dr. Von Korff has published over 120 papers in peer reviewed journals, and is a member of the NIMH Health Services Research study section. He has received awards for his research from the Academy of Psychosomatic Medicine and the American Association for the Study of Headache, and he is a Fellow of the Society for Behavioral Medicine and the Association for Health Services Research.

Dr. Wettstein is in the private practice of psychiatry, with an emphasis on legal and ethical practice issues. He is a consultant to the state licensing boards in medicine, psychology, nursing, dentistry, chiropractic, and law, and evaluates impaired professionals. He also conducts independent examinations regarding disability, workers compensation, and criminal responsibility.

Between 1984 and 1996, Dr. Wettstein was on the full-time faculty at WPIC, and was codirector of the Law and Psychiatry Program. He was involved in clinical consultations and treatment, and research activities in the law and psychiatry area. In 1996, he was awarded the "Golden Apple" award for excellence in teaching by the residents of WPIC.

Dr. Wettstein was Editor of the quarterly journal Behavioral Sciences and the Law until 1996. He is coauthor with Barbara Weiner, Esq. of Legal Issues in Mental Health Care. His edited volume, Treatment of Offenders with Mental Disorders, was published in 1998. He is also author of many other publications on legal and ethical issues in mental health care.

LEE K. WOLFSON, M.Ed.
Therapist, Depression and Manic Depression Prevention Program
Late Life Depression Program
Psychologist
Western Psychiatric Institute and Clinic
Pittsburgh, Pennsylvania

Lee Wolfson has provided interpersonal psychotherapy (IPT) and interpersonal and social rhythm therapy (IPSRT) since 1990 both in the Late Life Depression Studies and Bipolar Maintenance Study. He has authored and co-authored several scientific articles on IPT. He has presented IPT workshops and symposia at the American Association of Geriatric Psychiatry Annual meetings. He supervises psychiatric residents and psychology interns in IPT. He is certified in Problem Solving Therapy–P.C. and has collaborated in the development of Traumatic Grief Therapy.

Dr. Yurgelun-Todd is Director of Neuropsychology and Cognitive Neuroimaging, Brain Imaging Center, McLean Hospital and Assistant Professor of Psychiatry, Department of Psychiatry, Harvard Medical School. Her work has focused on the biological bases of psychotic disorders, and has included studies of neuropsychological performance, neurological hard signs, and brain morphometry. One particular aim has been to differentiate cortical abnormalities which are the result of psychiatric illness from brain anomalies which may represent risk factors for bipolar disorder and schizophrenia. She has successfully applied two new and powerful techniques in brain imaging, proton magnetic resonance spectroscopy and functional magnetic resonance imaging to the study of schizophrenia and bipolar disorder. Using complementary information on brain structure and function, Dr. Yurgelun-Todd’s studies have provided data regarding the course of metabolite changes, as well as data on functional brain activation in response to cognitive challenge paradigms. Dr. Yurgelun-Todd has been the recipient of an NIMH First Award for the application of proton spectroscopy to the temporal lobes of schizophrenic patients. She has also been the recipient of two Young Investigator Awards by the National Alliance for Research in Schizophrenia and Depression for the application of functional magnetic resonance imaging (fMRI) to the study of psychiatric disorders, and for the continued application of spectroscopic techniques to the study of psychotic patients. She has published on the applications of multiple neuroimaging techniques, neurocognitive function, treatment effects, risk factors, obstetrical complications and substance abuse to the study of psychiatric disorders, with special emphasis on schizophrenia and bipolar disorder. She currently serves as an editorial consultant for Schizophrenia Research, The American Journal of Psychiatry, and The Society for Biological Psychiatry. In addition to her research, Dr. Yurgelun-Todd is an active teacher of medical residents, post doctoral fellows, medical students, psychologists, graduate students and other trainees at McLean Hospital and Harvard Medical School.

Top of Page